| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11826343 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(16 years from now) | |
| US11633374 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(16 years from now) | |
| US11433046 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(16 years from now) | |
Eprontia is owned by Azurity.
Eprontia contains Topiramate.
Eprontia has a total of 3 drug patents out of which 0 drug patents have expired.
Eprontia was authorised for market use on 05 November, 2021.
Eprontia is available in solution;oral dosage forms.
Eprontia can be used as indicated for the preventive treatment of migraine in patients 12 years and older.
The generics of Eprontia are possible to be released after 21 August, 2040.
Drugs and Companies using
TOPIRAMATE ingredient
Market Authorisation Date:
05 November, 2021Treatment:
Indicated for the preventive treatment of migraine in patients 12 years and olderDosage:
SOLUTION;ORAL
How can I launch a generic of EPRONTIA before its drug patent expiration?
More Information on Dosage
EPRONTIA family patents
